Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03647488
Title Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications

lung non-small cell carcinoma

Therapies

Capmatinib + Spartalizumab

Docetaxel

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU | BEL

Facility Status City State Zip Country Details
Highlands Oncology Group Fayetteville Arkansas 72703 United States Details
Novartis Investigative Site Leuven 3000 Belgium Details
Novartis Investigative Site Grenoble 38043 France Details
Novartis Investigative Site LILLE Cédex 59037 France Details
Novartis Investigative Site Koeln 50937 Germany Details
Novartis Investigative Site Tel Aviv 6423906 Israel Details
Novartis Investigative Site Barcelona Catalunya 08036 Spain Details
Novartis Investigative Site Madrid 28009 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field